Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$13.14-1.72%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TNXP
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to grow commercial, Medicare, and Medicaid coverage to increase patient access to TONMYA for fibromyalgia treatment.
Stated as a priority in 3 quarters including 2026-Q1, 2026-Q2, and a July 2026 update. Coverage expanded from 35 million commercial lives in 2026-Q1 to approximately 136 million total lives by 2026-Q2, with a new Medicare agreement adding 9 million lives effective January 2027, totaling about 145 million lives. The trajectory is delivering consistent growth in patient access to TONMYA.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives).”
“Agreement signed in May with leading group purchasing organization (GPO) that provides access to TONMYA for approximately 35 million U.S. commercial lives.”
Progress the Phase 2 HORIZON study of TNX-102 SL as a first-line monotherapy for adults with major depressive disorder.
Stated as a priority in 2 quarters: 2026-Q1 and 2026-Q2. The first patient was enrolled in the Phase 2 HORIZON study by 2026-Q2, consistent with management's prior guidance to initiate enrollment mid-2026. The program is delivering on the planned clinical development timeline.
“First patient enrolled in Phase 2 HORIZON study of TNX-102 SL 5.6 mg for the treatment of major depressive disorder (MDD).”
“TNX-102 SL in Phase 2 development for MDD; remains on track to initiate mid-year 2026.”
Prepare to initiate an adaptive Phase 2 field study of TNX-4800, a monoclonal antibody for Lyme disease prevention, pending FDA agreement.
Stated as a priority in 3 disclosures including 2026-Q1, 2026-Q2, and August 2026 FDA meeting minutes. Management has maintained the plan to start the Phase 2 adaptive field study in early 2027 with FDA alignment on study design. The trajectory is delivering consistent progress toward clinical trial initiation.
“Phase 2 adaptive field study of TNX-4800 for Lyme disease prevention on track to start in Q1 2027 pending final FDA review and agreement on study protocol.”
“Expect to initiate adaptive Phase 2 field study for prevention of Lyme disease in the U.S. in first half of 2027 for TNX-4800, pending FDA agreement.”
Address recent executive changes including the retirement of the Chief Medical Officer and maintain leadership stability.
Newly stated in 2026-Q3 with the announcement of the Chief Medical Officer's retirement. No further financial or operational data is available to assess impact or progress on leadership transition.
Advance Phase 2-ready TNX-1500, a third-generation anti-CD40L monoclonal antibody, including investigator-initiated clinical study initiation pending FDA clearance.
Over the trailing year it converted 1.00x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
56 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.